The Value of Tumor Sample Analyses Before and After Checkpoint Inhibition: Contextualizing the Treatment-Induced Changes in Gene Expression

Lauren Folgosa Cooley, A. Gordon Robertson, Joshua J. Meeks*

*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceedingChapter


Although neoadjuvant cisplatin-based chemotherapy prior to radical cystectomy is the current standard of care for muscle-invasive bladder cancer (MIBC), immune checkpoint inhibitors have shown promising results in this setting. Phase II and III data of neoadjuvant programmed cell death-1 (PD-1) receptor/PD-1 ligand (PD-L1) inhibitors are now available with biomarker analyses of pre- and posttreatment tumors to help guide precision-based treatment to individual tumors. While still in its infancy, this review of available neoadjuvant immunotherapy trials (PURE-01, ABACUS, NABUCCO) and their biomarker analyses can contextualize the molecular and immunology-based biomarkers to improve prediction of individual patient response and outcomes.

Original languageEnglish (US)
Title of host publicationNeoadjuvant Immunotherapy Treatment of Localized Genitourinary Cancers
Subtitle of host publicationMultidisciplinary Management
PublisherSpringer International Publishing
Number of pages11
ISBN (Electronic)9783030805463
ISBN (Print)9783030805456
StatePublished - Jan 1 2022


  • Biomarkers
  • Bladder cancer
  • Immune response
  • Neoadjuvant checkpoint inhibition
  • Stroma

ASJC Scopus subject areas

  • Medicine(all)

Cite this